I’m a consultant radiologist with special focus on quantitative imaging and radiomics at the Department of Diagnostic and Interventional Radiology of the University Hospital Zurich. My special interest lies in the application of machine learning algorithms in medical imaging science with a focus on cardiac imaging. Currently, we are working on various projects where we aim to apply radiomics and deep learning to cardiac and oncological imaging as well as focusing on workflow improvements in radiology. Since these emerging technologies require large datasets to accurately evaluate their performance, I was able to take lead in a large nationwide multicenter trial aiming at standardizing quantitative cardiac MR and am also involved in a variety of ongoing oncological multicenter trials.
„Biography will be added soon“
Ronald Boellaard is full professor in medical physics and PET imaging methodology at the Amsterdam University Medical Centers and at the University Medical Center Groningen. His research focusses on PET pharmacokinetic analysis, image processing and analysis, radiomics and artificial intelligence, evaluation of new PET technologies and image reconstruction. He is member of several national and international committees that aim to enhance use of quantitative PET for research and in the clinic. He is the founder of and scientific advisor for the EARL PET/CT accreditation program and first author of the EANM oncology FDG PET/CT imaging guidelines. Presently, one of his main research topics concerns use of MATV and application of radiomics as imaging biomarkers in FDG PET/CT lymphoma studies. He published more than 350 peer reviewed articles and has an Hirsch-index of 72.
Bruce D. Cheson, M.D. was formerly Frank M. Ewing Chair in Hematology-Oncology, Professor of Medicine, Head of Hematology, Director of Center for Lymphoid Malignancies, and Deputy Chief, Hematology-Oncology at Georgetown University Hospital, Lombardi Comprehensive Cancer Center. Dr. Cheson has authored over 600 medical publications and contributed to over 60 texts. He is Editor in Chief of Annals of Lymphoma, former Editor-in-Chief of Clinical Advances in Hematology and Oncology, Clinical Lymphoma, Leukemia and Myeloma, and Associate Editor of the Journal of Clinical Oncology. He is past-Chair of the Lymphoma Committee of the Cancer and Leukemia Group B/Alliance, the Scientific Advisory Board of the Lymphoma Research Foundation, and the AJCC Subcommittee on Lymphoma. Dr. Cheson is currently Scientific Advisor to the Lymphoma Research Foundation. His interests focus on the development and evaluation of new therapeutic approaches for hematologic malignancies and measures of response.
Professor of the Jagiellonian University in Cracow, radiologist. His scientific achievements include 127 publications, the total Impact Factor 64, the Hirsch-index 10. The main area of interest and research work are modern medical diagnostic imaging methods and IT techniques used in the processing, transmission and presentation of imaging results. Since 2004, he has been performing multiparametric Magnetic Resonance Imaging examinations of the prostate gland. He also conducts cyclical training for radiologists in such assessment using the PIRADS standard. Since 2015, he has been cooperating with the Jagiellonian University Department of Hematology in the development of modern diagnostic imaging methods for multiple myeloma, in particular Whole Body Low Dose Computer Tomography. He is the author of the first Polish standard of performing such a study and implementation in clinical practice. Co-author of Polish guidelines for the diagnosis and treatment of renal cell carcinoma.
After receiving her MD degree in 2011, Anne-Ségolène was board certified by the French Society of Nuclear Medicine in 2015. She was appointed as Assistant Professor in the Nuclear Medicine department of Cochin Hospital- University Paris Descartes in 2019. She is a member of the Lymphoma Study Association imaging group as a reviewer for prospective trials. She aims to develop new imaging biomarkers in lymphoma using PET/CT imaging, to improve the outcomes of cancer patients by a better definition of prognostic subgroups at diagnosis. Her works have focused on metabolic tumor volume (MTV) across different lymphoma subtypes. She is currently involved in an international collaboration which aims to define a common methodological criteria for MTV measurement. More recently, she developed another PET biomarker reflecting lesion dissemination, the largest distance between two lesions to complement MTV and provide a predictive radiomic signature before treatment.
After studying medicine in Hamburg, Germany, and Montpellier, France, Professor Dührsen received his clinical training as an internist, hematologist, and oncologist at the university hospitals of Essen and Hamburg. He earned his doctoral degree with an experimental thesis on 5-hydroxytryptamine receptors, and extended his scientific training during a 3-year research period at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, where he worked on colony-stimulating factors and radiation-induced leukemias. In 1998, he was appointed full professor and director of the Department of Hematology at the University of Duisburg-Essen in Germany. His main fields of interest are clinical trials in leukemia, lymphoma, and myeloma, and experimental studies on the bone marrow microenvironment. In 2007, Professor Dührsen founded the PETAL study group whose goal is to define the role of positron emission tomography in aggressive lymphoma. He retired in 2020.
My name is Live Eikenes, and I work as an Associate Professor within the field of medical imaging at the Faculty of Medicine and Health Sciences at the Norwegian University of Science and Technology in Trondheim, Norway. In the early days of my academic carrier, I mainly worked with optimizing and analysis of diffusion weighted MRI within patient groups that are exposed to white matter damage such as preterm birth and traumatic brain injury, but also research on normal development and aging of white matter in healthy individuals. Since 2013, I have also worked with PET, when we got the first clinical simultaneous PET/MRI system installed in Norway, focusing on lymphoma and patients with brain tumors. In 2019, after many years of hard work raising funding for a clinical 7T MR scanner, a 7T MR scanner was established at St. Olav’s Hospital in Trondheim, and I will continue to expand my research to cover clinical 7T research within brain tumor applications.
Prof. Dr. Ken Herrmann, MBA graduated from Charite Berlin Medical School in 2004 after completing away electives and ERASMUS exchanges in France, Switzerland, Chile and the US. His further training included the Doctors Degree from Humboldt Universität Berlin (2007), board certification for Nuclear Medicine and habilitation (2010) at Technische Universität München and completion of the executive MBA program at Universität Zürich (2011). In May 2011 he joined as Visiting Assistant Professor and was later promoted to tenure track Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA. From 2012 to 2016 he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg. Since August 2016 Professor Herrmann acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen.
Wojciech Jurczak is a consultant and professor of hematology at Maria Sklodowska Curie National Research Institute of Oncology, in Cracow, Poland, where he is in charge of the Lymphoid Malignancy Dpt. Previously, since 1992, he led the Lymphoma Team at Jagiellonian University.
Most of his research activity in the first 15 years were related to development of monoclonal antibodies in B cell lymphomas, and practical aspects of stem cell transplantation. At that time radio-immunotherapy with Y90 labeled Ibritumomab tiuxetan was investigated, especially as consolidation of MCL and DLBCL patients, either in mono-therapy, or as an element of Z-BEAM conditioned ASCT.
In the last 15 years, establishing Pratia-MCM, a research facility, allowed the lymphoma team to take part in over 100 clinical trials, including phase I protocols. Wojciech Jurczak is a co-author of publications leading to registration of Ibrutinib, Acalabrutinib, Zanubrytynib, Idelalisib, Copanlisib, Umbralisib, Belinostat, Lenalidomide, Venetoclax, Brentuximab vedotin and Rituximab biosimilars. At present his research is focused on developing II and III generation BTK inhibitors, antiPD1 molecules, DARTs and BITEs. In collaboration with ICOS he initiates investigator sponsored studies assessing cardiotoxicity in lymphoma patients and methods of primary cardioprotection.
Being a member of EHA, PLRG and EMCLN, his papers were published in NEJM, Blood, JCO, The Lancet, Lancet Oncology, Annals of Oncology etc.
Prof. Dr. Carsten Kobe graduated from the University Hospital of Cologne. His further training included the Doctors Degree from University Freiburg, board certification for Nuclear Medicine and Habilitation at the University Hospital of Cologne. He has a broad interest in molecular imaging with a focus on quantification and hematological malignancies. He has published over 100 peer-reviewed articles and several book chapters in the Lancet, Journal of Clinical Oncology, Blood, Annals of Oncology and other major journals. As an active member of the Oncology & Theranostics Committee he supports the EANM annual Meetings.
Head of the Nuclear Medicine Department of the Nantes University Hospital and co-leader of the Nuclear Oncology Research team of the Centre de Recherche en Cancérologie et Immunologie de Nantes-Angers (CRCINA INSERM UMR1232), Françoise Kraeber-Bodéré has been particularly involved over the last 15 years in the design of academic first-in-human and multicenter clinical studies assessing innovative radiopharmaceuticals in oncology, in close collaboration with industrial partners and cooperative groups. She is expert of the Oncology and Therapy committee of the European Society of Nuclear Medicine and member of the scientific and administrative boards of the French Lymphoma cooperative group LYSA. She also participates to the French Myeloma cooperative group IFM as PET expert. She has been PI of numerous trials of radionuclide therapy, PET and immuno-PET and is the leader of the IRON Excellence Lab since 2012. She participated in more than 180 international publications (H Index 35).
Dr. Jolanta Kunikowska is a nuclear medicine as well as internal medicine physician specialist. She is currently assistant professor at the Nuclear Medicine Department, Medical University, Warsaw/Poland. She has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and theragnostics (radionuclide therapy). She has a particular interest in novel PET radiotracers, and theragnostic applications including prostate, neuroendocrine tumors and glioblastoma. She has authored over 90 peer-reviewed articles and several book chapters. She received several prestigious awards provided by various scientific communities including the Gold prize for Hisada award in 2018 and Marie Curie Award for outstanding scientific work presented at the 29th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona in 2016. She is currently the President of the EANM.
Dr. Egesta Lopci has graduated cum laude in Medicine and Surgery at the University of Bologna, Italy. At the same University she finished cum laude her specialization in Nuclear Medicine and completed her PhD in Specialized Medical Sciences. From 2017 till 2019, she followed the EORTC ECI Leadership programme. In 2017, she obtained the Italian scientific qualification as Professor in Diagnostic Imaging and Radiotherapy. As Nuclear Medicine Consultant she is directly involved in clinical and research activities with particular interest on nuclear oncology, focusing on tumor response assessment and immunotherapy. She is an active member of different organizations and research groups, comprising AIEOP Hodgkin Lymphoma Interest Group, EANM Oncology Committee, EORTC Imaging and Lung Cancer Groups, UEMS/EBNM CME Accreditation Committee, and is Chair of the EORTC IG Educational Subcommittee. Over the years, she has won several grants and more than 10 awards and recognitions for her research.
„Biography will be added soon“
„Biography will be added soon”
Marcel Nijland is a hematologist at the University Medical Center Groningen. He received his board certification in 2012. His main focus is translational research in aggressive B-cell lymphomas, involving immune escape, gene expression profiles, mutational analysis, circulating tumor DNA (ctDNA) and molecular imaging. He is in involved in more than 25 clinical trials. He is the principal investigator (PI) of the HOVON 151 trial with atezolizumab consolidation in patients with a diffuse large B-cell lymphoma, as well as several non-interventional studies. One of the major challenges in lymphomas is the selection of patients who benefit the most of novel targeted therapy, especially the monoclonal antibodies and chimeric antigen T-cell therapy. Molecular imaging (MI) could possibly help to bridge the gap between basic biology and optimal patient selection. To this end in collaboration with local collaborators and pharmaceutical companies, he has setup 2 MI studies in DLBCL (89Zr-atezolizumab and 89Zr-brentuximab)
Dr. Paula Rodríguez-Otero studied medicine at the University of Navarra, Pamplona, Spain. Subsequently she completed her residency training program in hematology at the Clinic of the University of Navarra and became faculty at the department of the same institution. After completing her PhD she focused her clinical interest in the management and biology of allogeneic stem cell transplant, which brought her to perform a clinical fellowship in the bone marrow transplant division at the Hôpital Saint-Louis, in Paris. In 2011 she joined back the Department of Hematology at the University of Navarra, where she has become a member of the Myeloma Unit and leads the clinical trials and immunotherapy program under the direction of Professor Jesus San Miguel.
Prof. Dr. Nadia Withofs, MD, PhD, received her medical degree from the University of Liege, Belgium. She did her residency in nuclear medicine in the Division of Nuclear Medicine and Oncological Imaging at the University hospital of Liege. She was research scholar in the Pr. Sam S. Gambhir’s laboratory in the Molecular Imaging Program at Stanford (USA) in 2008-2009. She holds a PhD in medical sciences and investigated [18F]FPRGD2 PET/CT imaging of integrins. She works full time in the division of nuclear medicine of the CHU of Liege and GIGA-CRC in vivo imaging lab of ULiege. She has a particular interest in imaging myeloma & lymphoma, prostate cancer and osteoarthritis. She has been appointed assistant lecturer at ULiege since March 2020. She was the general secretary of the Belgian Society of Nuclear Medicine (BELNUC) in 2018-2019. She is associate editor of The British Journal of Radiology and the Journal of the French Society of Nuclear medicine.
Elena Zamagni MD, PHD, is Associate Professor of Hematology at the Bologna University, Italy. She received her medical degree from University of Bologna, where she also served her residency in haematology. She got PHD in Clinical Hematology at the University of Bologna in May 2005. Her research interests include areas related to multiple myeloma, in particular on the role of high dose therapy with stem cell support, of prognostic factors, minimal residual disease and of imaging techniques. She has published over 120 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She has contributed to the educational session of the Italian Society of Haematology (SIE) and American Society of Clinical Oncology (ASCO). She is abstracts reviewer for SIE, EHA and ASH. She is part of the editorial board of several haematological journals. She is an active member of the board of the GIMEMA and European Myeloma Network (EMN) working party and she has cooperated in the Scientific program committee for the European Society of Hematology.